Dr. Hao’s research interests focus on economic evaluations of health services and programs which aim to improve patient outcomes through promoting individualized/precision healthcare. Specifically, in 3 sub-areas:
- Economic evaluation of genome sequencing and pharmacogenomics. Project examples include: MyCode return of results to patients and providers, HLA-B*1502 genotyping and carbamazepine induced side effects
- Economic evaluation of risk-stratified cancer prevention and treatment approach. Relevant projects include: new staging system of Squamous Cell Carcinomas of the Oropharynx, and risk-prediction biomarker test which predicts progression risk of Barrett’s esophagus to esophageal adenocarcinoma
- Economic evaluation of pharmacy innovation, e.g. innovative patient managements of biologics use in psoriasis population with aims to improve health outcome and contain costs.
The quantitative research methods she uses include decision analysis modeling and simulation, biostatistics and econometrics methods by utilizing electronic health records, claims data, both internal and national cost data sources and by systematic evidence synthesis.
- Hao J, Snyder, SR, Pitcavage JM, Critchley-Thorne RJ. A Cost-Effectiveness Analysis of a Cancer Risk Prediction Test for Patients with Barrett's Esophagus. Gastroenterology. 2016; 150:3: S260-S261.
- Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):127-34. PubMed PMID: 26174631.
- Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS One. 2015 Oct 15;10(10):e0140708. PubMed PMID: 26469277.
EducationMD, Shanxi Medical University, 1999-2004
MS, Shanghai Jiaotong University School of Medicine, 2004-2007
MPH, University of Massachusetts Amherst, 2007-2009
PhD, University of Massachusetts Amherst, 2009-2015